Why do benign astrocytomas become malignant in NF1?
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Many patients with NF1 develop severe medical complications over their life span, as they do the major NF1 manifestations—café-au-lait spots, skin-fold freckling, iris Lisch nodules, and neurofibromas.1,3,5⇓⇓ Forty to 60% of children will have learning disabilities, variable cognitive impairment,6,7⇓ attention difficulties, and impairment of gross and fine coordination.4,7⇓ Patients can also have abnormal brain development: megalencephaly, enlargement of the corpus callosum, increased overall white matter volume, and areas of abnormal signal on MRI (“unidentified bright objects” or UBO).8 Patients with NF1 may be shorter than the average person, have larger than average head circumferences, and may also have thoracic abnormalities.1,4⇓ Other disease manifestations include osseous and vascular dysplasias.1,3,5⇓⇓ Plexiform neurofibromas occur in 25 to 50% of patients with NF1, with an increase in incidence over the life of the patient, and may involve many regions of the body, causing neurologic or cosmetic deficits; they also may evolve to malignant peripheral nerve sheath tumors.1,3,9⇓⇓
Patients with NF1 have a risk of malignancy as high as four- to sixfold above normal, including primary CNS tumors, malignant peripheral sheath tumors, rhabdomyosarcomas, and various leukemias.1,9⇓ There is little evidence, however, for the existence of NF1 pedigrees with strong cancer predisposition.10 Of the CNS tumors, optic pathway gliomas are the most common, occuring in 10 to 20% of patients at risk.11,12⇓ Gliomas elsewhere in the brain and ependymomas …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Alert Me
Recommended articles
-
Views & Reviews
Eliminating barriers to personalized medicineLearning from neurofibromatosis type 1David H. Gutmann et al.Neurology, June 27, 2014 -
Articles
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomasJun Li, Arie Perry, C. David James et al.Neurology, April 10, 2001 -
Article
A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1Jasia Mahdi, Amish C. Shah, Aimee Sato et al.Neurology, March 22, 2017 -
Biomarkers
Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical UseChetan Bettegowda, Meena Upadhayaya, D. Gareth Evans et al.Neurology, July 06, 2021